{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T03:10:28Z","timestamp":1775099428372,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1124\/dmd.120.090928","type":"journal-article","created":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T04:17:23Z","timestamp":1593749843000},"page":"769-777","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Drug-Drug Interaction Risk Assessment of Esaxerenone as a Perpetrator by In Vitro Studies and Static and Physiologically Based Pharmacokinetic Models"],"prefix":"10.1016","volume":"48","author":[{"given":"Makiko","family":"Yamada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Ishizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronika","family":"Rozehnal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.120.090928_bib1","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ejphar.2015.06.015","article-title":"Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist","volume":"761","author":"Arai","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/dmd.120.090928_bib2","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1124\/jpet.116.234765","article-title":"CS-3150, a novel nonsteroidal mineralocorticoid receptor antagonist, shows preventive and therapeutic effects on renal injury in deoxycorticosterone acetate\/salt-induced hypertensive rats","volume":"358","author":"Arai","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.120.090928_bib3","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ejphar.2015.11.028","article-title":"CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats","volume":"769","author":"Arai","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/dmd.120.090928_bib4","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1124\/dmd.104.002436","article-title":"The binding of drugs to hepatocytes and its relationship to physicochemical properties","volume":"33","author":"Austin","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.090928_bib5","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1365-2125.2005.02483.x","article-title":"Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant","volume":"60","author":"Brown","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.120.090928_bib6","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/clpt.2009.253","article-title":"A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor\/inducer tipranavir\/ritonavir","volume":"87","author":"Dumond","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.120.090928_bib7","unstructured":"Food and Drug Administration (2020) In vitro drug interaction studies \u2014 cytochrome P450 enzyme- and transporter-mediated drug interactions guidance for industry, US Department of Health and Human Services, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD."},{"issue":"Suppl 1","key":"10.1124\/dmd.120.090928_bib8","first-page":"S38","article-title":"The effect of multiple oral administration of esaxerenone on the pharmacokinetics of midazolam in healthy Japanese males (Abstract)","volume":"75","author":"Furuie","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.120.090928_bib9","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s11095-012-0918-y","article-title":"Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug-drug interaction potential","volume":"30","author":"Gertz","year":"2013","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.120.090928_bib10","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.xphs.2018.10.033","article-title":"Physiologically based pharmacokinetic modeling in regulatory science: an update from the U.S. Food and Drug Administration\u2019s Office of Clinical Pharmacology","volume":"108","author":"Grimstein","year":"2019","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.120.090928_bib11","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2125.2010.03799.x","article-title":"Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models","volume":"71","author":"Guest","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.120.090928_bib12","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/cpt.1183","article-title":"Advancing predictions of tissue and intracellular drug concentrations using in vitro, imaging and physiologically based pharmacokinetic modeling approaches","volume":"104","author":"Guo","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.120.090928_bib13","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s40262-018-0635-8","article-title":"Predictive performance of physiologically-based pharmacokinetic models in predicting drug\u2013drug interactions involving enzyme modulation","volume":"57","author":"Hsueh","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.120.090928_bib14","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0031-6997(24)01372-3","article-title":"Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver","volume":"50","author":"Ito","year":"1998","journal-title":"Pharmacol Rev"},{"key":"10.1124\/dmd.120.090928_bib15","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/s41371-019-0207-x","article-title":"Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study","volume":"33","author":"Ito","year":"2019","journal-title":"J Hum Hypertens"},{"key":"10.1124\/dmd.120.090928_bib16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","article-title":"Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN study)","volume":"75","author":"Ito","year":"2020","journal-title":"Hypertension"},{"key":"10.1124\/dmd.120.090928_bib17","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2215\/CJN.14751218","article-title":"Efficacy and safety of esaxerenone (CS-3150) for the treatment of type 2 diabetes with microalbuminuria: a randomized, double-blind, placebo-controlled, phase II trial","volume":"14","author":"Ito","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1124\/dmd.120.090928_bib18","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/cpt.37","article-title":"Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective","volume":"97","author":"Jones","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.120.090928_bib19","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1111\/bcp.13616","article-title":"Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects","volume":"84","author":"Kato","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.120.090928_bib20","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/clpt.2011.164","article-title":"Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy","volume":"90","author":"Katzenmaier","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.120.090928_bib21","doi-asserted-by":"crossref","unstructured":"Kirigaya Y, Shiramoto M, Ishizuka T, Uchimaru H, Irie S, Kato M, Shimizu T, Nakatsu T, Nishikawa Y, Ishizuka H (2020a) Effects of itraconazole and rifampicin on the single-dose pharmacokinetics of the nonsteroidal mineralocorticoid receptor blocker esaxerenone in healthy Japanese subjects. Br J Clin Pharmacol. DOI: 10.1111\/bcp.14302 [published ahead of print]","DOI":"10.1111\/bcp.14302"},{"key":"10.1124\/dmd.120.090928_bib22","doi-asserted-by":"crossref","unstructured":"Kirigaya Y, Shiramoto M, Ishizuka T, Uchimaru H, Irie S, Kato M, Shimizu T, Nakatsu T, Nishikawa Y, Ishizuka H (2020b) Pharmacokinetic interactions of esaxerenone with amlodipine and digoxin in healthy Japanese subjects. BMC Pharmacol Toxicol in press.","DOI":"10.1186\/s40360-020-00423-4"},{"key":"10.1124\/dmd.120.090928_bib23","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1007\/s12325-019-00956-z","article-title":"Absolute bioavailability of esaxerenone and food effects on its pharmacokinetics after a single oral dose in healthy Japanese subjects: an open-label crossover study","volume":"36","author":"Kurata","year":"2019","journal-title":"Adv Ther"},{"key":"10.1124\/dmd.120.090928_bib24","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/bdd.2058","article-title":"The absorption kinetics of ketoconazole plays a major role in explaining the reported variability in the level of interaction with midazolam: interplay between formulation and inhibition of gut wall and liver metabolism","volume":"38","author":"Liu","year":"2017","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/dmd.120.090928_bib25","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/0091270012440282","article-title":"Comprehensive assessment of human pharmacokinetic prediction based on in vivo animal pharmacokinetic data, part 2: clearance","volume":"53","author":"Lombardo","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.120.090928_bib26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1177\/0091270012440281","article-title":"Comprehensive assessment of human pharmacokinetic prediction based on in vivo animal pharmacokinetic data, part 1: volume of distribution at steady state","volume":"53","author":"Lombardo","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.120.090928_bib27","unstructured":"Pharmaceutical Evaluation Division, Pharmaceuticals Safety and Environmental Health BureauMinistry of Labor and Welfare (2018) Guideline on drug interaction for drug development and appropriate provision of information, Pharmaceutical Evaluation Division, Pharmaceuticals Safety and Environmental Health Bureau, Ministry of Labor and Welfare, Tokyo, Japan."},{"key":"10.1124\/dmd.120.090928_bib28","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/s41440-019-0314-7","article-title":"Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension","volume":"42","author":"Rakugi","year":"2019","journal-title":"Hypertens Res"},{"key":"10.1124\/dmd.120.090928_bib29","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ddtec.2004.10.002","article-title":"\u2018In silico\u2019 simulations to assess the \u2018in vivo\u2019 consequences of \u2018in vitro\u2019 metabolic drug-drug interactions","volume":"1","author":"Rostami-Hodjegan","year":"2004","journal-title":"Drug Discov Today Technol"},{"key":"10.1124\/dmd.120.090928_bib30","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/cpt.1013","article-title":"Physiologically based pharmacokinetic model qualification and reporting procedures for regulatory submissions: a consortium perspective","volume":"104","author":"Shebley","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.120.090928_bib31","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0009-9236(96)90177-0","article-title":"Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism","volume":"59","author":"Thummel","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.120.090928_bib32","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/clpt.2013.187","article-title":"Evaluation of various static in vitro-in vivo extrapolation models for risk assessment of the CYP3A inhibition potential of an investigational drug","volume":"95","author":"Vieira","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.120.090928_bib33","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1124\/dmd.119.089599","article-title":"Critical impact of drug-drug interactions via intestinal CYP3A in the risk assessment of weak perpetrators using physiologically based pharmacokinetic models","volume":"48","author":"Yamada","year":"2020","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.090928_bib34","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1124\/dmd.118.084897","article-title":"Pharmacokinetics, metabolism, and excretion of [14C]esaxerenone, a novel mineralocorticoid receptor blocker in humans","volume":"47","author":"Yamada","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.090928_bib35","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1080\/00498254.2016.1263766","article-title":"Pharmacokinetics, distribution, and disposition of esaxerenone, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist, in rats and monkeys","volume":"47","author":"Yamada","year":"2017","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.120.090928_bib36","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1124\/dmd.106.013359","article-title":"Misuse of the well-stirred model of hepatic drug clearance","volume":"35","author":"Yang","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.090928_bib37","doi-asserted-by":"crossref","first-page":"676","DOI":"10.2174\/138920007782109733","article-title":"Prediction of intestinal first-pass drug metabolism","volume":"8","author":"Yang","year":"2007","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.120.090928_bib38","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1124\/dmd.112.048892","article-title":"A perspective on the contribution of metabolites to drug-drug interaction potential: the need to consider both circulating levels and inhibition potency","volume":"41","author":"Yu","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.090928_bib39","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1124\/dmd.109.026658","article-title":"Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite","volume":"37","author":"Zhang","year":"2009","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562407781X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562407781X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.120.090928","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T09:23:07Z","timestamp":1739956987000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009095562407781X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S009095562407781X"],"URL":"https:\/\/doi.org\/10.1124\/dmd.120.090928","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-Drug Interaction Risk Assessment of Esaxerenone as a Perpetrator by In Vitro Studies and Static and Physiologically Based Pharmacokinetic Models","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.120.090928","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}